Prosecutors in Tokyo yesterday carried out the first arrests in connection with an accounting scandal that’s shaved 50% from the value of Olympus Corp. (TYO:7733) since last October.
Cynosure Inc.
Masimo meets The Street, shares rise | Earnings Roundup
Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
Ortho market growth stable but low | Wall Street Beat
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
AngioDynamics CEO: Navilyst deal hits the reset button | Wall Street Beat
Updated February 1, 2012 at 5:30 p.m.
The $372 million buyout of Navilyst Medical by AngioDynamics (NSDQ:ANGO) is a reset button that will reinforce the combined operation for the future, AngioDynamics CEO Joe DeVivo told MassDevice this afternoon.
Medtronic lands FDA clearance, plans launch for next-gen CRM lead | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) landed FDA clearance for its DF4 high-voltage right ventricular lead for use with implantable cardiac rhythm management devices.
The DF4, which builds on Medtronic’s Sprint Quattro lead, aims to help simplify the implantation process with a redesigned port and by providing visual confirmation of the lead’s connection to the device.
BSX offers 10 year warranties on newly cleared defibrillators | Regulatory Roundup
Boston Scientific Corp. (NYSE:BSX) landed FDA clearance for its Incepta, Energen and Punctua cardiac implants to treat heart failure and sudden cardiac death.
To go along with the new defibrillator systems, the Natick, Mass.-based med-tech titan is providing an extended warranty for the Incepta and Energen family of defibrillators.
3M’s Q3 profits slide despite sales boost | Earnings Roundup
Shares of 3M Co. (NYSE:MMM) lost nearly 6 percent today after the conglomerate reported a 1.6 percent profit slide for the third quarter and slashed its sales and earnings guidance for 2011.
3M reported profits of $1.09 billion, or $1.52 per share, on sales of $7.53 billion. That’s a top-line increase of 9.6 percent compared with Q3 2010. Wall Street analysts expected $1.61 per share for the latest quarter.
Philips’ health care division reports “strong growth and a healthy order book” | Earnings Roundup
Updated: 7/28/2011 10:30 a.m.
Royal Philips Electronics’ (NYSE:PHG) health care division posted modest second quarter growth while the company overall slid hard into the red on weak markets and impairment charges.
"Healthcare achieved robust growth of 8 percent, exceeding expectations," newly appointed president & CEO Frans van Houten said during a conference call with investors.
Cynosure picks up aesthetic laser business for $24.5 million | Acquisitions roundup
Cynosure Inc. (NSDQ:CYNO) announced the $24.5 million acquisition of the assets of Japan-based HOYA ConBio’s aesthetic laser business today.
The Westford, Mass.-based cosmetic laser device maker adds HOYA’s proprietary PhotoAcoustic energy technology to its product portfolio, which also includes the SmoothShapes cellulite reduction system.
The PhotoAcoustic technology uses high-speed energy waves to penetrate skin in nanoseconds, minimizing the amount of heat in each procedure.
Revolutions Medical taps new CFO | Personnel Moves
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
Cellulite: Cynosure touts regulatory wins for laser fat-removal products | Regulatory roundup
Cynosure Inc. (NSDQ:CYNO) officials said the company has won international regulatory approval for two of its cellulite reduction systems, including the SmoothShapes laser liposuction device that sucked $40 million out of now-defunct Elemé Medical Inc.